Search research articles
Contact Us
Filters
Showing results (1-10 of 5) with videos related to
Page
of 1
Sort By:
Cancer Chemotherapy and Pharmacology
|
June 5, 1999
Promising new developments in cancer chemotherapy
K Ferrante, B Winograd, R Canetta
The American Journal of Gastroenterology
|
August 1, 1995
Treatment of hepatocellular carcinoma with transjugular intrahepatic portosystemic shunting and chemoembolization
K Stuart, H Anastopoulos, K Ferrante, et al.
Neurology
|
February 9, 2005
Detection of serum reverse transcriptase activity in patients with ALS and unaffected blood relatives
A J Steele, A Al-Chalabi, K Ferrante, et al.
Cancer
|
July 11, 1998
A phase II trial of 5-fluorouracil, leucovorin, and carboplatin in patients with unresectable biliary tree carcinoma
P M Sanz-Altamira, K Ferrante, R L Jenkins, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 4, 2001
Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies
M Hidalgo, L L Siu, J Nemunaitis, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 5) with videos related to
Sort By:
Page
of 1
Cancer Chemotherapy and Pharmacology
|
June 5, 1999
Promising new developments in cancer chemotherapy
K Ferrante, B Winograd, R Canetta
The American Journal of Gastroenterology
|
August 1, 1995
Treatment of hepatocellular carcinoma with transjugular intrahepatic portosystemic shunting and chemoembolization
K Stuart, H Anastopoulos, K Ferrante, et al.
Neurology
|
February 9, 2005
Detection of serum reverse transcriptase activity in patients with ALS and unaffected blood relatives
A J Steele, A Al-Chalabi, K Ferrante, et al.
Cancer
|
July 11, 1998
A phase II trial of 5-fluorouracil, leucovorin, and carboplatin in patients with unresectable biliary tree carcinoma
P M Sanz-Altamira, K Ferrante, R L Jenkins, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 4, 2001
Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies
M Hidalgo, L L Siu, J Nemunaitis, et al.
Page
of 1